{"id":"W2275911521","doi":"10.1200/jco.2012.30.15_suppl.559","title":"Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Exemestane; Everolimus; Anastrozole; Hazard ratio; Internal medicine; Aromatase inhibitor; Letrozole; Clinical endpoint; Interim analysis; Progression-free survival; Breast cancer; Oncology; Population; Cancer; Randomized controlled trial; Tamoxifen; Confidence interval; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005488275,0.0009055462,0.001824176,0.0004339395,0.0002394701,0.001175533,0.0008095931,0.0009848967,0.003652749],"category_scores_gemma":[0.002834692,0.0004087455,0.001561111,0.0006334212,0.0003777371,0.0007891768,0.000433553,0.001704862,0.0007748241],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008060014,"about_ca_system_score_gemma":0.001149188,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001176374,"about_ca_topic_score_gemma":0.003905159,"domain_scores_codex":[0.9990615,0.0005636303,0.00006751405,0.0000908215,0.0001388049,0.00007776476],"domain_scores_gemma":[0.9987823,0.0003104352,0.0004864951,0.00008496034,0.00008644101,0.0002493061],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.717651,0.003647357,0.01262435,0.005289855,0.007900698,0.0002447381,0.0001936693,0.002321498,0.009723475,0.0005203546,0.03142861,0.2084544],"study_design_scores_gemma":[0.8257653,0.05125134,0.05746067,0.00130365,0.01048556,0.0007339371,0.00008015291,0.001204393,0.00160186,0.0007632783,0.04925671,0.00009317154],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6157654,0.3187758,0.001914426,0.008152891,0.001275872,0.004655893,0.02979827,0.0004044078,0.01925705],"genre_scores_gemma":[0.7957676,0.10326,0.007649169,0.01163289,0.001616239,0.008098386,0.06043353,0.0002012897,0.01134076],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005488275,"threshold_uncertainty_score":0.02902514,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07042906341995182,"score_gpt":0.4663861042031853,"score_spread":0.3959570407832335,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}